TY - JOUR
T1 - ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery)
T2 - A Randomized Trial
AU - Ott, Ilka
AU - Cassese, Salvatore
AU - Groha, Philipp
AU - Steppich, Birgit
AU - Voll, Felix
AU - Hadamitzky, Martin
AU - Ibrahim, Tareq
AU - Kufner, Sebastian
AU - Dewitz, Karl
AU - Wittmann, Theresa
AU - Kasel, Albert Markus
AU - Laugwitz, Karl Ludwig
AU - Schunkert, Heribert
AU - Kastrati, Adnan
AU - Fusaro, Massimiliano
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2017
Y1 - 2017
N2 - Background-—Paclitaxel-eluting balloon (PEB) angioplasty has superior efficacy compared with conventional balloon angioplasty (BA) for de novo lesions of superficial femoral artery (SFA). Studies investigating the angiographic and clinical performance of PEB angioplasty versus BA for in-stent restenosis of SFA are limited. We performed a randomized trial to investigate angiographic and clinical performance of PEB versus BA for in-stent restenosis of SFA. Methods and Results-—Patients with symptomatic in-stent restenosis of SFA were randomly assigned to either PEB or BA at 2 centers in Munich, Germany. The primary end point was the percentage diameter stenosis at 6- to 8-month follow-up angiography. Secondary end points were the rate of binary restenosis at follow-up angiography and target lesion revascularization, target vessel thrombosis, ipsilateral amputation, bypass surgery of the affected limb, and all-cause mortality at 24-month follow-up. Seventy patients were assigned to PEB (n=36) or BA (n=34). Mean lesion length was 13967 mm, and roughly one third of lesions were completely occluded at the time of the index procedure. At control angiography, the percentage diameter stenosis (4433% versus 6533%, P=0.01) and binary restenosis were significantly reduced with PEB versus BA (30% versus 59%, P=0.03). At 24-month follow-up, PEB was associated with a significant reduction of target lesion revascularization in comparison to BA (19% versus 50%, P=0.007). There was no difference with respect to other outcomes of interest. Conclusions-—In patients with in-stent restenosis of SFA, a percutaneous therapy with PEB compared with BA has superior angiographic performance at 6 to 8 months and improved clinical efficacy up to 24-month follow-up. Clinical Trial Registration-—URL: Http://www.clinicaltrials.gov. Unique identifier: NCT01083394. (J Am Heart Assoc. 2017;6: E006321. DOI: 10.1161/JAHA.117.006321.).
AB - Background-—Paclitaxel-eluting balloon (PEB) angioplasty has superior efficacy compared with conventional balloon angioplasty (BA) for de novo lesions of superficial femoral artery (SFA). Studies investigating the angiographic and clinical performance of PEB angioplasty versus BA for in-stent restenosis of SFA are limited. We performed a randomized trial to investigate angiographic and clinical performance of PEB versus BA for in-stent restenosis of SFA. Methods and Results-—Patients with symptomatic in-stent restenosis of SFA were randomly assigned to either PEB or BA at 2 centers in Munich, Germany. The primary end point was the percentage diameter stenosis at 6- to 8-month follow-up angiography. Secondary end points were the rate of binary restenosis at follow-up angiography and target lesion revascularization, target vessel thrombosis, ipsilateral amputation, bypass surgery of the affected limb, and all-cause mortality at 24-month follow-up. Seventy patients were assigned to PEB (n=36) or BA (n=34). Mean lesion length was 13967 mm, and roughly one third of lesions were completely occluded at the time of the index procedure. At control angiography, the percentage diameter stenosis (4433% versus 6533%, P=0.01) and binary restenosis were significantly reduced with PEB versus BA (30% versus 59%, P=0.03). At 24-month follow-up, PEB was associated with a significant reduction of target lesion revascularization in comparison to BA (19% versus 50%, P=0.007). There was no difference with respect to other outcomes of interest. Conclusions-—In patients with in-stent restenosis of SFA, a percutaneous therapy with PEB compared with BA has superior angiographic performance at 6 to 8 months and improved clinical efficacy up to 24-month follow-up. Clinical Trial Registration-—URL: Http://www.clinicaltrials.gov. Unique identifier: NCT01083394. (J Am Heart Assoc. 2017;6: E006321. DOI: 10.1161/JAHA.117.006321.).
KW - In-stent restenosis
KW - paclitaxel-eluting balloon
KW - peripheral artery disease
UR - http://www.scopus.com/inward/record.url?scp=85040961791&partnerID=8YFLogxK
U2 - 10.1161/JAHA.117.006321
DO - 10.1161/JAHA.117.006321
M3 - Article
C2 - 28743787
AN - SCOPUS:85040961791
SN - 2047-9980
VL - 6
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 7
M1 - e006321
ER -